Francis Mhimbira

In the News

Muhas don is new IHI board member

Prof. Kaaya. Ifakara Health Institute (IHI) Board of Governors (BOG) has appointed Prof. Sylvia Kaaya member of the IHI Board of Trustees (BOT) effective Wednesday January 10, 2018. The appointment …

Marcel steps down from IHI boards

Prof. Marcel Tanner has stepped down as Ifakara Health Institute (IHI) member of the Board of Trustees (BOT) and Board of Governors (BOG) effective Wednesday January 10, 2018. The Former …

Recent Projects

Development of a new tool for malaria mosquito surveillance to improve vector control

Malaria transmission is influenced not only by vector abundance, but as well by demographic traits such as vector species and age structure, as these influence the intensity by which the …

Demonstrating complete disruption of residual malaria transmission by eliminating Anopheles funestus mosquitoes from rural Tanzanian villages

In rural south-eastern Tanzania, where malaria prevalence has reduced by >60% since 2000, low-to-moderate transmission still persists despite very high coverage with long-lasting insecticidal bednets. Like in most residual transmission …

Francis Mhimbira

Research Scientist and Head of Interventions & Clinical Trials

Dr. Francis Mhimbira is an epidemiologist and a research scientist based at Ifakara Health Institute. Dr. Mhimbira received his medical degree at Muhimbili University College of Health Sciences (MUCHS), Tanzania, and did a Masters degree in Epidemiology from The University of Melbourne, Australia. He works within the intervention thematic group and conducts research on TB clinical trials for new drugs and vaccines. His work also involves evaluating new TB diagnostic tools and epidemiological studies on TB and co-infections (such as HIV, helminth and respiratory pathogens). Francis also does operational research to improve TB case detection and improve TB treatment outcomes. He is currently a national and principal investigator of Phase III clinical trial (NC-006) of new TB drugs and regimen. Francis is currently the Head of Interventions and Clinical Trials Department.

View Dr. Mhimbira’s Research Interests and Publications


Evaluation of combinations of bedaquiline, moxifloxacin, PA‐824 and pyrazinamide for treatment of newly-diagnosed TB patients

Evaluation of efficacy, safety and tolerability of a three-drug regimen (Moxifloxacin+PA‐824+Pyrazinamide) for TB and MDR-TB

© Ifakara Health Institute (IHI), 2016